Genetic Analysis of Diffuse High‐Grade Astrocytomas in Infancy Defines a Novel Molecular Entity

Pediatric high‐grade gliomas are considered to be different when compared to adult high‐grade gliomas in their pathogenesis and biological behavior. Recently, common genetic alterations, including mutations in the H3F3A/ATRX/DAXX pathway, have been described in approximately 30% of the pediatric cases. However, only few cases of infant high‐grade gliomas have been analyzed so far. We investigated the molecular features of 35 infants with diffuse high‐grade astrocytomas, including 8 anaplastic astrocytomas [World Health Organization (WHO) grade III] and 27 glioblastomas (WHO grade IV) by immunohistochemistry, multiplex ligation probe‐dependent amplification (MLPA), pyrosequencing of glioma‐associated genes and molecular inversion probe (MIP) assay. MIP and MLPA analyses showed that chromosomal alterations are significantly less frequent in infants compared with high‐grade gliomas in older children and adults. We only identified H3F3A K27M in 2 of 34 cases (5.9%), with both tumors located in the posterior fossa. PDGFRA amplifications were absent, and CDKN2A loss could be observed only in two cases. Conversely, 1q gain (22.7%) and 6q loss (18.2%) were identified in a subgroup of tumors. Loss of SNORD located on chromosome 14q32 was observed in 27.3% of the infant tumors, a focal copy number change not previously described in gliomas. Our findings indicate that infant high‐grade gliomas appear to represent a distinct genetic entity suggesting a different pathogenesis and biological behavior.

[1]  Gabriele Schackert,et al.  Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling , 2014, International journal of cancer.

[2]  T. Pietsch,et al.  Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous system , 2014, Neuropathology and applied neurobiology.

[3]  G. Reifenberger,et al.  Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild‐type glioblastoma , 2014, Genes, chromosomes & cancer.

[4]  T. Pietsch,et al.  FGFR1 N546K mutation in a case of papillary glioneuronal tumor (PGNT) , 2014, Acta Neuropathologica.

[5]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[6]  F. Gilles,et al.  Long‐term survival of children less than six years of age enrolled on the CCG‐945 phase III trial for newly‐diagnosed high‐grade glioma: A report from the Children's Oncology Group , 2014, Pediatric blood & cancer.

[7]  David T. W. Jones,et al.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.

[8]  T. Pietsch,et al.  Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma , 2013, British Journal of Cancer.

[9]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[10]  S. Croul,et al.  The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas , 2013, Modern Pathology.

[11]  C. Kramm,et al.  H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. , 2013, American journal of clinical pathology.

[12]  S. Savola,et al.  Multiplex Ligation-dependent Probe Amplification (MLPA) in Tumor Diagnostics and Prognostics , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[13]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[14]  Andrey Korshunov,et al.  Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.

[15]  F. Jiang,et al.  Small nucleolar RNAs in cancer. , 2012, Biochimica et biophysica acta.

[16]  B. Kleinschmidt-DeMasters,et al.  Clinical and molecular characteristics of congenital glioblastoma. , 2012, Neuro-oncology.

[17]  J. Schiffman,et al.  Molecular inversion probes: a novel microarray technology and its application in cancer research. , 2012, Cancer genetics.

[18]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[19]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[20]  J. Y. Lee,et al.  Long-term outcomes in children with glioblastoma. , 2010, Journal of neurosurgery. Pediatrics.

[21]  Zhenqiu Liu,et al.  Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer , 2010, Molecular Cancer.

[22]  A. Ashworth,et al.  A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas , 2010, Clinical Cancer Research.

[23]  Richard G Grundy,et al.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Giangaspero,et al.  Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas , 2010, Journal of Neuro-Oncology.

[25]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[26]  Wei Zhou,et al.  Implication of snoRNA U50 in human breast cancer. , 2009, Journal of genetics and genomics = Yi chuan xue bao.

[27]  M. Mourtada-Maarabouni,et al.  GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer , 2009, Oncogene.

[28]  Tarik Tihan,et al.  Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium , 2008, Cancer.

[29]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[30]  A. Kibel,et al.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. , 2007, Human molecular genetics.

[31]  T. Merchant,et al.  High‐grade astrocytoma in very young children , 2007, Pediatric blood & cancer.

[32]  D. Brat,et al.  Congenital Glioblastoma: A Clinicopathologic and Genetic Analysis , 2007, Brain pathology.

[33]  J. Ko,et al.  Functional evidence of decreased tumorigenicity associated with monochromosome transfer of chromosome 14 in esophageal cancer and the mapping of tumor‐suppressive regions to 14q32 , 2005, Genes, chromosomes & cancer.

[34]  H. Jürgens,et al.  Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases. , 2001, The American journal of pathology.

[35]  H. Satoh,et al.  Intronic U50 small‐nucleolar‐RNA (snoRNA) host gene of no protein‐coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B‐cell lymphoma , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  D. Machin,et al.  Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. , 2010, European journal of cancer.

[37]  Thomas E Merchant,et al.  Brain tumors across the age spectrum: biology, therapy, and late effects. , 2010, Seminars in radiation oncology.

[38]  Webster K. Cavenee,et al.  WHO Classification of Tumours of the Central Nervous System. 4th Ed. , 2007 .

[39]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[40]  I. Pollack,et al.  The Relationship between TPS 3 Mutations and Overexpression of p 53 and Prognosis in Malignant Gliomas of Childhood ' , 2022 .